- Home
- EAT vs LEGN Comparison
EAT vs LEGN Comparison
Compare EAT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAT
- LEGN
- Stock Information
- Founded
- EAT 1975
- LEGN 2014
- Country
- EAT United States
- LEGN United States
- Employees
- EAT N/A
- LEGN N/A
- Industry
- EAT Restaurants
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EAT Consumer Discretionary
- LEGN Health Care
- Exchange
- EAT Nasdaq
- LEGN Nasdaq
- Market Cap
- EAT 7.0B
- LEGN 7.0B
- IPO Year
- EAT N/A
- LEGN 2020
- Fundamental
- Price
- EAT $150.90
- LEGN $27.80
- Analyst Decision
- EAT Hold
- LEGN Strong Buy
- Analyst Count
- EAT 16
- LEGN 13
- Target Price
- EAT $144.36
- LEGN $75.67
- AVG Volume (30 Days)
- EAT 2.0M
- LEGN 1.6M
- Earning Date
- EAT 04-29-2025
- LEGN 05-13-2025
- Dividend Yield
- EAT N/A
- LEGN N/A
- EPS Growth
- EAT 113.08
- LEGN N/A
- EPS
- EAT 7.16
- LEGN N/A
- Revenue
- EAT $5,130,500,000.00
- LEGN $728,303,000.00
- Revenue This Year
- EAT $22.26
- LEGN $65.96
- Revenue Next Year
- EAT $4.69
- LEGN $52.55
- P/E Ratio
- EAT $21.00
- LEGN N/A
- Revenue Growth
- EAT 19.80
- LEGN 112.46
- 52 Week Low
- EAT $56.27
- LEGN $29.27
- 52 Week High
- EAT $192.22
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- EAT 55.66
- LEGN 29.31
- Support Level
- EAT $135.00
- LEGN $30.25
- Resistance Level
- EAT $152.82
- LEGN $33.30
- Average True Range (ATR)
- EAT 5.97
- LEGN 1.72
- MACD
- EAT 1.23
- LEGN -0.41
- Stochastic Oscillator
- EAT 67.64
- LEGN 3.14
About EAT Brinker International Inc.
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.